Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Wiley

Pediatrics Mobile, AL Medical Doctor

NPI 1902896004 CMS profile 787855

2560 Old Shell Rd, Mobile, AL 36607

Open in the dashboard

General payments

$43,923

647 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Wiley of Mobile, AL is reported in the CMS Open Payments database as having received $43,923 across 647 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,191 76
2024 General $6,576 93
2023 General $1,399 96
2022 General $1,373 92
2021 General $5,299 120
2020 General $3,547 59
2019 General $22,539 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Wiley
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to James Wiley were reported at $3,191. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year James Wiley Pediatrics median Middle half National median
2019 $22,539 $86 $31–$183 $163
2020 $3,547 $49 $22–$110 $114
2021 $5,299 $68 $27–$158 $132
2022 $1,373 $77 $30–$173 $149
2023 $1,399 $88 $33–$190 $160
2024 $6,576 $94 $34–$206 $164
2025 $3,191 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $22,280 188 payments
  2. Ironshore Pharmaceuticals Inc. $12,776 90 payments
  3. Supernus Pharmaceuticals, Inc. $4,599 111 payments
  4. Corium, Inc. $1,874 80 payments
  5. Neos Therapeutics, LP $1,252 102 payments
  6. Adlon Therapeutics L.P. $327 25 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $223 17 payments
  8. Collegium Pharmaceutical, Inc. $222 12 payments
  9. Shire North American Group Inc $178 10 payments
  10. Vertical Pharmaceuticals, LLC $142 8 payments
  11. Other $52 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $17,050 14 payments
  2. Food and Beverage $11,073 597 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,980 6 payments
  4. Travel and Lodging $5,389 25 payments
  5. Consulting Fee $280 1 payment
  6. Education $131 3 payments
  7. Gift $20 1 payment
Products named General payments · program years 2019–2025
  1. Dyanavel XR Adhd $14,029 84 payments
  2. Jornay PM 20mg capsules (Bottle of 100) $11,725 40 payments
  3. Dyanavel XR Adhd $7,986 93 payments
  4. Quillichew ER Adhd $6,888 8 payments
  5. Quillivant Adhd $6,888 8 payments
  6. Quillivant Adhd $3,743 10 payments
  7. Quillichew ER Adhd $3,650 4 payments
  8. Quillivant XR $2,647 7 payments
  9. Quillichew ER Adhd $2,600 4 payments
  10. Azstarys $1,874 80 payments
  11. Other $5,217 365 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

32

Median for Pediatric Medicine: 38

Drug cost

$669

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 17 $385
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 15 $284

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Dyanavel XR
  • Tris Pharma Inc $1,911
$1,911 — —
Quillivant
  • Tris Pharma Inc $1,629
$1,629 — —
Quillichew ER
  • Tris Pharma Inc $1,629
$1,629 — —
Azstarys
  • Corium, Inc. $596
$596 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $393
$393 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

647 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record